DS-1040b + Placebo + Enoxaparin
Phase 1/2Completed 1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pulmonary Embolism
Conditions
Pulmonary Embolism, Thrombotic Disease
Trial Timeline
Jun 23, 2016 → Aug 5, 2019
NCT ID
NCT02923115About DS-1040b + Placebo + Enoxaparin
DS-1040b + Placebo + Enoxaparin is a phase 1/2 stage product being developed by Daiichi Sankyo for Pulmonary Embolism. The current trial status is completed. This product is registered under clinical trial identifier NCT02923115. Target conditions include Pulmonary Embolism, Thrombotic Disease.
What happened to similar drugs?
20 of 20 similar drugs in Pulmonary Embolism were approved
Approved (20) Terminated (1) Active (0)
✅Arformoterol Tartrate Inhalation Solution + Arformoterol Tartrate Inhalation Solution + PlaceboSumitomo PharmaApproved
Hype Score Breakdown
Clinical
9
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02923115 | Phase 1/2 | Completed |
Competing Products
20 competing products in Pulmonary Embolism